Alemtuzumab in the treatment of multiple sclerosis

Journal of Inflammation Research

Volumn 7, Issue 1, 2014, Pages 19-27

  Fernandez, Óscar ^a  

^a HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

Author keywords

Alemtuzumab; Interferon beta 1a; Monoclonal antibody; Multiple sclerosis; New therapies; Treatment

Indexed keywords

ALEMTUZUMAB; BETA1A INTERFERON; CORTICOSTEROID; FINGOLIMOD; IMMUNOGLOBULIN; INTERLEUKIN 21; NATALIZUMAB; RITUXIMAB; TERIFLUNOMIDE;

ADULT; ARTICLE; AUTOIMMUNE DISEASE; B LYMPHOCYTE; BRADYCARDIA; BRAIN HEMORRHAGE; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOPENIA; DISEASE ACTIVITY; DISEASE COURSE; DISEASE DURATION; DRUG APPROVAL; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; EXPANDED DISABILITY STATUS SCALE; FEMALE; FEVER; GLOMERULONEPHRITIS; HEADACHE; HUMAN; INFECTION; LIVER DISEASE; LYMPHOCYTE SUBPOPULATION; MALE; MEMBRANOUS GLOMERULONEPHRITIS; MULTIPLE SCLEROSIS; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; QT PROLONGATION; RASH; RELAPSE; REMISSION; T LYMPHOCYTE; THROMBOCYTOPENIC PURPURA; THYROID DISEASE;

EID: 84894557668     PISSN: None     EISSN: 11787031     Source Type: Book Series    
DOI: 10.2147/JIR.S38079     Document Type: Article

References (33)

1. Coles AJ, Wing MG, Molyneux P, et al. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol. 1999;46(3):296-304.
2. Moreton P, Kennedy B, Lucas G, et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol. 2005;23(13):2971-2979.
3. Schnitzer TJ, Yocum DE, Michalska M, et al. Subcutaneous administration of CAMPATH-1H: clinical and biological outcomes. J Rheumatol. 1997;24(6):1031-1036.
4. Lim SH, Hale G, Marcus RE, Waldmann H, Baglin TP. CAMPATH-1 monoclonal antibody therapy in severe refractory autoimmune thrombocytopenic purpura. Br J Haematol. 1993;84(3):542-544.
5. Lockwood CM, Thiru S, Isaacs JD, Hale G, Waldmann H. Long-term remission of intractable systemic vasculitis with monoclonal antibody therapy. Lancet. 1993;341(8861):1620-1622.
6. Lockwood CM, Thiru S, Stewart S, et al. Treatment of refractory Wegener's granulomatosis with humanized monoclonal antibodies. QJM. 1996;89(12):903-912.
7. Coles AJ, Cox A, Le Page E, et al. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol. 2006;253(1):98-108.
8. European Medicines Agency. European Public Assessment Report (Alemtuzumab). London: European Medicines Agency; 2013. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/003718/WC500150522.pdf. Accessed October 15, 2013.
9. Osterborg A, Dyer MJ, Bunjes D, et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. J Clin Oncol. 1997;15(4):1567-1574.
10. European Medicines Agency. Summary of Product Characteristics (Alemtuzumab). London: European Medicines Agency; 2013. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003718/WC500150521.pdf. Accessed October 15, 2013.
11. Hale G, Rebello P, Brettman LR, et al. Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration. Blood. 2004;104(4):948-955.
12. Brown JW, Coles AJ. Alemtuzumab: evidence for its potential in relapsing-remitting multiple sclerosis. Drug Des Devel Ther. 2013;7: 131-138.
13. Cox AL, Thompson SA, Jones JL, et al. Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis. Eur J Immunol. 2005;35(11):3332-3342.
14. Jones JL, Anderson JM, Phuah CL, et al. Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity. Brain. 2010;133(Pt 8):2232-2247.
15. CAMMS223 Trial Investigators, Coles AJ, Compston DA, et al. Alemtuzumab vs interferon beta-1a in early multiple sclerosis. N Engl J Med. 2008;359(17):1786-1801.
16. Cohen JA, Coles AJ, Arnold DL, et al; CARE-MS I investigators. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet. 2012;380(9856):1819-1828.
17. Coles AJ, Twyman CL, Arnold DL, et al; CARE-MS II investigators. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet. 2012;380(9856):1829-1839.
18. Filippini G, Del Giovane C, Vacchi L,. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis. Cochrane Database Syst Rev. 2013;6:CD008933.
19. Galetta SL, Markowitz C, Lee AG. Immunomodulatory agents for the treatment of relapsing multiple sclerosis: a systematic review. Arch Intern Med. 2002;162(19):2161-2169.
20. Panitch H, Goodin DS, Francis G, et al; EVIDENCE Study Group. Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial. Neurology. 2002;59(10): 1496-1506.
21. Schwid SR, Panitch HS. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis. Clin Ther. 2007;29(9): 2031-2048.
22. Polman CH, O'Connor PW, Havrdova E, et al; AFFIRM Investigators. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899-910.
23. Moreau T, Thorpe J, Miller D, et al. Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis. Lancet. 1994;344(8918): 298-301.
24. Paolillo A, Coles AJ, Molyneux PD, et al. Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H. Neurology. 1999;53(4):751-757.
25. Hirst CL, Pace A, Pickersgill TP, et al. Campath 1-H treatment in patients with aggressive relapsing remitting multiple sclerosis. J Neurol. 2008;255(2):231-238.
26. Wynn D, Arnold DL, Coles AJ, et al. Detection, incidence, and management of glomerulonephritis in the alemtuzumab clinical development program. Poster P597 presented at: 29th Congress of the European Committee for Research and Treatment in Multiple Sclerosis (ECTRIMS); October 2-5, 2013; Copenhagen, Denmark.
27. Costelloe L, Jones J, Coles A. Secondary autoimmune diseases following alemtuzumab therapy for multiple sclerosis. Expert Rev Neurother. 2012;12(3):335-341.
28. Niederwieser G, Buchinger W, Bonelli RM, et al. Prevalence of autoimmune thyroiditis and non-immune thyroid disease in multiple sclerosis. J Neurol. 2003;250(6):672-675.
29. Oh J, O'Connor PW. An update of teriflunomide for treatment of multiple sclerosis. Ther Clin Risk Manag. 2013;9:177-190.
30. Deiß A, Brecht I, Haarmann A, Buttmann M. Treating multiple sclerosis with monoclonal antibodies: a 2013 update. Expert Rev Neurother. 2013;13(3):313-335.
31. Ali R, Nicholas RS, Muraro PA. Drugs in development for relapsing multiple sclerosis. Drugs. 2013;73(7):625-650.
32. Gold R, Kappos L, Arnold DL, et al; DEFINE Study Investigators. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012;367(12):1098-1107.
33. Kappos L, Li D, Calabresi PA, et al. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet. 2011;378(9805):1779-1787.